open access

Vol 57, No 4 (2006)
Review article
Published online: 2006-07-07
Submitted: 2013-02-15
Get Citation

Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer - update of current and our own experiences

Kornelia Hasse-Lazar, Daria Handkiewicz-Junak, Józef Roskosz, Sylwia Szpak-Ulczok, Jolanta Krajewska, Beata Jurecka-Lubieniecka, Barbara Jarząb
Endokrynologia Polska 2006;57(4):445-451.

open access

Vol 57, No 4 (2006)
Review article
Published online: 2006-07-07
Submitted: 2013-02-15

Abstract

Traditionally, for diagnostic and therapeutic application of radioiodine in patients with differentiated thyroid cancer (DTC), a 4 to 6 week withdrawal of thyroid hormone was applied. Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without withdrawal of thyroid hormone and associated morbidity. The results of rhTSH administration and endogenous TSH stimulation are equivalent in detecting recurrent DTC. At the present time rhTSH is approved as an adjunct for diagnostic procedures and thyroid ablation in patients with DTC. In addition, rhTSH has potential for use in facilitating the treatment of metastases in patients with DTC. In this review we have summarized our own experiences with rhTSH aided radioiodine therapy in patients with disseminated thyroid cancer. Generally, rhTSH was very well tolerated and treatment results were comparable to those achieved with thyroid hormone withdrawal.

Abstract

Traditionally, for diagnostic and therapeutic application of radioiodine in patients with differentiated thyroid cancer (DTC), a 4 to 6 week withdrawal of thyroid hormone was applied. Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without withdrawal of thyroid hormone and associated morbidity. The results of rhTSH administration and endogenous TSH stimulation are equivalent in detecting recurrent DTC. At the present time rhTSH is approved as an adjunct for diagnostic procedures and thyroid ablation in patients with DTC. In addition, rhTSH has potential for use in facilitating the treatment of metastases in patients with DTC. In this review we have summarized our own experiences with rhTSH aided radioiodine therapy in patients with disseminated thyroid cancer. Generally, rhTSH was very well tolerated and treatment results were comparable to those achieved with thyroid hormone withdrawal.
Get Citation

Keywords

differentiated thyroid cancer; rhTSH; radiodine treatment

About this article
Title

Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer - update of current and our own experiences

Journal

Endokrynologia Polska

Issue

Vol 57, No 4 (2006)

Pages

445-451

Published online

2006-07-07

Bibliographic record

Endokrynologia Polska 2006;57(4):445-451.

Keywords

differentiated thyroid cancer
rhTSH
radiodine treatment

Authors

Kornelia Hasse-Lazar
Daria Handkiewicz-Junak
Józef Roskosz
Sylwia Szpak-Ulczok
Jolanta Krajewska
Beata Jurecka-Lubieniecka
Barbara Jarząb

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl